Year archive

Swedish Orphan Biovitrum — 2015 filings

All 52 regulatory filings released by Swedish Orphan Biovitrum (SOBI) in 2015, sourced directly from the official regulator.

52 Filings

2015 Period

2015 filings (52)

Filing	Released	Lang
Lars Dreiøe blir Senior Vice President, Chief Quality & Compliance Officer på Sobi Board/Management Information	2015-12-21	Swedish
Lars Dreiøe joins Sobi as Senior Vice President, Chief Quality & Compliance Officer Board/Management Information	2015-12-21	English
Sobi och Biogens Elocta® (rFVIIIFc) godkänd i Europa för behandling av hemofili A Regulatory Filings	2015-11-24	Swedish
Sobi and Biogen's Elocta® (rFVIIIFc) approved in Europe for the treatment of haemophilia A Regulatory Filings	2015-11-24	English
Interim / Quarterly Report 2015 Interim / Quarterly Report Q3 2015	2015-10-29	Swedish
Interim / Quarterly Report 2015 Interim / Quarterly Report Q3 2015	2015-10-29	English
Sobi publishes its Report for the Third Quarter 2015 Interim / Quarterly Report Q3 2015	2015-10-29	English
Sobi publicerar sin rapport för det tredje kvartalet 2015 Interim / Quarterly Report Q3 2015	2015-10-29	Swedish
New number of shares and votes in Swedish Orphan Biovitrum AB (publ) Declaration of Voting Results & Voting Rights Announcements	2015-09-30	English
Ändring av antalet aktier och röster i Swedish Orphan Biovitrum AB (publ) Share Issue/Capital Change	2015-09-30	Swedish
Sobis VD investerar i 2015 års LTI-program och avyttrar del av insitamentsaktier Remuneration Information	2015-09-29	Swedish
Sobi CEO invests in 2015 LTI programme and divests a portion of incentive shares Director's Dealing	2015-09-29	English
Biogen and Sobi receive positive opinion from CHMP for Elocta(TM) (rFVIIIFc) for the treatment of Haemophilia A Regulatory Filings	2015-09-25	English
Biogen och Sobi erhåller CHMP rekommendation för Elocta(TM) (rFVIIIFc) för behandling av hemofili A Regulatory Filings	2015-09-25	Swedish
Swedish Orphan Biovitrum AB (publ) : The board of directors exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under the incentive programme Transaction in Own Shares	2015-09-11	English
Swedish Orphan Biovitrum AB (publ) : Styrelsen utnyttjar återköpsbemyndigande för säkerställande av bolagets åtaganden enligt incitamentsprogram Share Issue/Capital Change	2015-09-11	Swedish
Interim / Quarterly Report 2015 Interim / Quarterly Report Q2 2015	2015-07-16	Swedish
Interim / Quarterly Report 2015 Interim / Quarterly Report Q2 2015	2015-07-16	English
Sobi publishes its Report for the Second Quarter 2015 - raises guidance Interim / Quarterly Report Q2 2015	2015-07-16	English
Sobi publicerar sin rapport för det andra kvartalet 2015 - höjer utsikterna Interim / Quarterly Report Q2 2015	2015-07-16	Swedish
Kommuniké från Sobis årsstämma AGM Information	2015-06-30	Swedish
Resolutions from Sobi's Annual General Meeting AGM Information	2015-06-30	English
Biogen och Sobi meddelar att den Europeiska läkemedelsmyndigheten validerat ansökan om marknadsföringstillstånd för Alprolix® (rFIXFc) Regulatory Filings	2015-06-26	Swedish
Biogen and Sobi announce European Medicines Agency validates Alprolix® (rFIXFc) marketing authorisation application Earnings Release FY 2015	2015-06-26	English
Sobis styrelse avslutar samtal om icke-bindande förslag M&A Activity	2015-06-08	Swedish
Sobi Board of Directors terminates discussions regarding non-binding proposal M&A Activity	2015-06-08	English
Sobis samarbetspartner Biogen ansöker om marknadsgodkännande för Alprolix® (rFIXFc) i Europa Regulatory Filings	2015-06-04	Swedish
Sobi's partner Biogen submits marketing authorisation application for Alprolix® (rFIXFc) in Europe Regulatory Filings	2015-06-04	English
Kallelse till årsstämma i Swedish Orphan Biovitrum AB (publ) AGM Information	2015-05-27	Swedish
Notice of annual general meeting in Swedish Orphan Biovitrum AB (publ) AGM Information	2015-05-27	English
Sobi publishes its Report for the First Quarter 2015 Interim / Quarterly Report Q1 2015	2015-05-06	English
Sobi publicerar sin rapport för första kvartalet 2015 Interim / Quarterly Report Q1 2015	2015-05-06	Swedish
Interim / Quarterly Report 2015 Interim / Quarterly Report Q1 2015	2015-05-06	Swedish
Interim / Quarterly Report 2015 Interim / Quarterly Report Q1 2015	2015-05-06	English
Sobi's Board of Directors postpones Annual General Meeting of Shareholders AGM Information	2015-04-29	English
Sobis styrelse senarelägger årsstämman AGM Information	2015-04-29	Swedish
Statement regarding recent speculation M&A Activity	2015-04-27	English
Uttalande angående pågående spekulationer M&A Activity	2015-04-27	Swedish
Swedish Orphan Biovitrum AB (publ) : Sobis årsredovisning för 2014 publicerad Annual Report FY 2014	2015-04-15	Swedish
Swedish Orphan Biovitrum AB (publ) : Sobi publishes Annual Report 2014 Annual Report FY 2014	2015-04-15	English
Annual Report 2014 Annual Report FY 2014	2015-04-15	Swedish
Annual Report 2014 Annual Report FY 2014	2015-04-15	English
Notice of annual general meeting in Swedish Orphan Biovitrum AB (publ) AGM Information	2015-03-30	English
Kallelse till årsstämma i Swedish Orphan Biovitrum AB (publ) AGM Information	2015-03-30	Swedish
Biogen Idec and Sobi announce positive top-line efficacy and safety results from phase 3 Alprolix® paediatric study Earnings Release FY 2015	2015-02-27	English
Biogen Idec och Sobi meddelar positiva effekt- och säkerhetsresultat från företagens fas-3-studie på barn av läkemedelskandidaten Alprolix® (rFIXFc) för hemofili B Regulatory Filings	2015-02-27	Swedish
Sobi publicerar sin rapport för fjärde kvartalet och bokslutskommuniké för 2014 Audit Report / Information FY 2014	2015-02-19	Swedish
Sobi publishes its Report for the Fourth Quarter and Full Year 2014 Interim / Quarterly Report FY 2014	2015-02-19	English
Audit Report / Information 2014 Audit Report / Information FY 2014	2015-02-19	Swedish
Interim / Quarterly Report 2014 Interim / Quarterly Report FY 2014	2015-02-19	English
Xiapex® får EU-godkännande för behandling av Peyronies sjukdom Regulatory Filings	2015-01-30	Swedish
Xiapex approved by the EU Commission for the treatment of Peyronie's disease Regulatory Filings	2015-01-30	English

Filings by year

2026 16 filings
2025 35 filings
2024 29 filings
2023 48 filings
2022 23 filings
2021 31 filings
2020 44 filings
2019 38 filings
2018 31 filings
2017 34 filings
2016 47 filings
2015 52 filings
2014 58 filings
2013 79 filings
2012 65 filings
2011 51 filings
2010 78 filings
2009 69 filings
2008 51 filings
2007 10 filings